Stock·NASDAQ·Healthcare
BioNTech SE (BNTX)
- Market cap
- $22.66B
- Dividend yield
- 0.00%
- Street target
- $123.11median of 21 analysts
- 52-week range
- $79.52 $124.00
The short version
Where BNTX stands today, in four lines, and what CleaRank Financial AI makes of it.
BNTX at a glance
BioNTech SE (BNTX): Sell, 21/100 on CleaRank's AI score.
- Trend Down: the price is below both its 50- and 200-day moving averages ($98.78 and $97.67).
- Earnings BNTX beat estimates in 2 of its last 6 quarters, yet fell the next day after every one of them.
- Insiders Insiders sold $74.3M and made no open-market purchases over the last 18 months.
Figures as of October 16, 2026.
CleaRank Financial AI
BioNTech SE (BNTX) is trading at $87.53, significantly below its 50-day and 200-day moving averages ($98.78 and $97.67), indicating a bearish trend.
The company has experienced a substantial revenue decline of -59.5% year-over-year, and its profit margin is significantly negative at -63.64%. This fundamental weakness is compounded by significant insider selling, with $74.3 million in dispositions across recent filings, leading to a 'Heavy Sell Signal' verdict. While Wall Street analysts maintain a 'Buy' consensus with a median price target of $123.11, suggesting a 40.7% upside, the overwhelming insider selling and deteriorating financial metrics present a compelling bearish case.
Only on CleaRank
Figures we compute ourselves from BNTX's own price, earnings and insider-filing history. Tap one to see it in context.
Price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
1/4Price above its 50-day average ›
The price of $87.53 is 11.4% below the 50-day simple moving average of $98.78.Price above its 200-day average ›
The price is 10.4% below the 200-day simple moving average of $97.67.50-day average above the 200-day ›
The 50-day average ($98.78) is 1.1% above the 200-day average ($97.67), the arrangement of a rising longer-term trend.In the upper half of its 52-week range ›
The price sits at 18% of its 52-week range, between $79.52 and $124.00.
BNTX share price
Pick a period: each tab shows how far BNTX has moved over it, to the last close.
Today's trading
Where BNTX sits inside today's range and its 52-week range.
Fundamentals
Valuation against the sector, and the revenue and earnings behind it.
Valuation and quality checks
0/3P/S below the sector median ›
The price-to-sales ratio of 8.55 is 151.5% above the sector median of 3.4.Profitable over the last 12 months ›
Net income over the last 12 months was $-1.9B on revenue of $3.0B, a net margin of -63.6%.Beat estimates in most recent reports ›
BNTX beat the EPS estimate in 2 of its last 6 reports.
Key statistics
The headline figures for BNTX.
As of October 16, 2026, BNTX trades at $87.53, with a market value of $22.66B and no P/E ratio (its trailing earnings are negative).
What the numbers say
CleaRank Financial AI's reading of BNTX's valuation, growth and risks.
BioNTech SE (BNTX) exhibits a concerning fundamental picture, with a negative EPS of -7.83 and a significantly negative profit margin of -63.64%.
The company's revenue has contracted by 59.5% year-over-year, a stark contrast to the sector's median revenue growth of 8.1%. The return on equity is negative at -9.30%. The current valuation metrics are overshadowed by the company's struggle to generate positive earnings and revenue growth.
BNTX against the Healthcare sector
How BNTX compares with the median Healthcare stock CleaRank tracks.
Price to sales vs sector: On price-to-sales, the yardstick used here in place of P/E, BNTX trades at 8.55x, +151% versus the sector average of 3.40x.
Return vs XLV: Since May 5, 2025, BNTX has lost 10.8% against a gain of 28.3% for XLV.
Performance against XLV
BNTX and the Healthcare sector fund over the same days.
Revenue and earnings
How much BNTX sells, and how much of it becomes profit.
Revenue growth: Revenue grew 4.3% in FY2025 to €2.9B, from €2.8B a year earlier.
Profit margin: The net margin was -39.6% in FY2025, down from -24.2% the year before.
Loss-making: BNTX lost €1.1B in FY2025.
Earnings reality check
Did BNTX beat what analysts expected, and how did the stock react?
Earnings record: BNTX beat the analyst estimate in 2 of the last 6 quarters.
Market reaction: The stock fell in the first session after 2 of those 2 beats, so a beat has not been enough on its own.
| Report | Estimate | Actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| May 5, 2026after close | -$1.92 | -$1.95 | -1.56% | -0.25% | -1.93% |
| Mar 10, 2026after close | -$0.25 | -$0.33 | -32.00% | +8.28% | +13.08% |
| Nov 3, 2025after close | $0.10 | -$0.12 | -220.00% | +0.84% | +1.07% |
| Aug 4, 2025after close | -$1.41 | -$1.60 | -13.48% | +0.95% | -0.70% |
| May 5, 2025after close | -$2.35 | -$1.73 | +26.38% | -6.29% | -3.79% |
| Mar 10, 2025after close | $0.37 | $1.08 | +191.89% | -6.61% | -4.26% |
Reports after May 5, 2026 are not yet in our data.
As of October 16, 2026, BNTX has beaten the analyst EPS estimate in 2 of its last 6 reported quarters and fell in the first trading session after 2 of those beats; its most recent report in our data, on May 5, 2026, came in 1.56% below the estimate and the stock moved -0.25% in the first session.
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
AI analysis and technicals
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
1/3RSI not overbought or oversold ›
The 14-day RSI is 35.1, showing bearish momentum without being oversold.RSI above 50 ›
An RSI of 35.1 is below the 50 midpoint, so sellers have had the upper hand over the last 14 days.MACD line above zero ›
The MACD line is negative, so the 12-day average is below the 26-day average.
CleaRank AI analysis of BNTX
The score, the reasoning behind it, and what could move the price next.
BioNTech SE (BNTX) is currently trading at $87.53, below its 20-day EMA ($94.48), 50-day SMA ($98.78), and 200-day SMA ($97.67), signaling a strong bearish trend.
The 14-day RSI is at 35.07, indicating bearish momentum, and the MACD is at -2.54. Key support levels are not clearly defined given the downward trajectory, and resistance is expected at the aforementioned moving averages.
Wall Street Buy Consensus and Price Target ›
Despite negative fundamentals, 21 Wall Street analysts maintain a 'Buy' consensus with a median price target of $123.11, suggesting a potential 40.7% upside.
Source: Analyst Reports
Heavy Insider Selling Pressure ›
Insiders have sold $74.3 million worth of BioNTech SE stock across recent filings, indicating a 'Heavy Sell Signal' and raising concerns about management's confidence in future performance.
Source: Insider Trading DataSignificant Revenue Contraction ›
BioNTech SE reported a year-over-year revenue decline of 59.5%, highlighting a critical challenge in its business operations and growth prospects.
Source: Company FinancialsBearish Technical Momentum ›
The stock is trading below its key moving averages (50-day SMA, 200-day SMA, 20-day EMA) with a bearish RSI status, suggesting continued downward price pressure.
Source: Technical Analysis
- The significant insider selling totaling $74.3 million warrants extreme caution, suggesting potential headwinds not fully captured by analyst targets.
- With BNTX trading below its 50-day and 200-day moving averages ($98.78 and $97.67) and showing bearish RSI momentum, consider waiting for a clear technical reversal before initiating long positions.
Technical indicators
Momentum and trend for BNTX, from its daily closes.
As of October 16, 2026, with BNTX at $87.53, its 14-day RSI is 35.1 (showing bearish momentum without being oversold), its 50-day simple moving average is $98.78 and its 200-day is $97.67.
Calculated by CleaRank on daily closes as of October 16, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26).
What BNTX moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of October 16, 2026, BNTX's 1-year correlation of daily returns is +0.30 with S&P 500 (SPY), +0.25 with Nasdaq 100 (QQQ), +0.25 with Bitcoin (BTC) and +0.19 with gold (XAU).
What Wall Street expects
The analysts' target range and how their ratings split.
Analysts checks
2/3Most analysts rate it a buy ›
14 of 21 analysts rate it a buy or strong buy, 7 a hold and 0 a sell.Median target above the price ›
The median 12-month target of $123.11 is 40.7% above the price.More buy ratings than three months ago ›
14 of 21 rate it a buy now, against 15 of 20 three months ago.
BNTX Wall Street View
12-month price targets
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Oct 7, 2026 | Morgan Stanley | Maintains | Overweight |
| Sep 8, 2026 | BMO Capital | Downgrade | Market Perform |
| Aug 31, 2026 | Canaccord Genuity | Maintains | Buy |
| Aug 5, 2026 | Citigroup | Maintains | Buy |
| Aug 5, 2026 | Evercore ISI Group | Maintains | Outperform |
| Jul 8, 2026 | Morgan Stanley | Maintains | Overweight |
As of October 16, 2026, 21 Wall Street analysts cover BNTX: 14 rate it a buy or strong buy, 7 a hold and 0 a sell or strong sell. Their 12-month price targets range from $76.10 to $144.19, with a median of $123.11, 40.7% above the price of $87.53.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
A trade plan, if you want one
Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.
BNTX trade plan
Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.
Short entry pick an entry style
Risk management
Profit targets (Based on Conservative Entry)
These levels come from BNTX's moving averages and recent volatility, not from a forecast. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Risk profile
How much BNTX tends to move, against the market and on its own.
The long record
BNTX's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
1/4Average daily move under 2% ›
The price has moved 2.46% on an average day (30-day standard deviation of daily returns).Recovered from its worst fall ›
The worst fall was 81.9%, from August 2021 to July 2024; the price is still 80.2% below that peak.Most 1-year holds ended higher ›
44% of 1-year holding periods in the last 7 years ended with a gain.Beat the S&P 500 since the chart begins ›
$10,000 invested in October 2019 is now worth $64,171, against $29,078 in the S&P 500 (SPY).
BNTX Drawdowns & Recovery
As of October 16, 2026, BNTX's worst peak-to-trough fall over the last 7 years with dividends reinvested was -81.9% (August 2021 to July 2024); it is still 80.2% below that peak, and 44% of 1-year holding periods ended with a gain.
From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into BNTX in October 2019 is worth now, against the same amount in the S&P 500.
Against the market: BNTX beat the S&P 500 over this period: $64,171 against $29,078.
A $10,000 investment in BNTX in October 2019 would be worth about $64,171 today with dividends reinvested, compared with about $29,078 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
Seasonal patterns
Which calendar months have been kind to BNTX, and which have not.
Strongest month, November: an average of +13.93%, up in 6 of 7 years.
Weakest month, January: an average of -3.46%, up in 3 of 7 years.
This month, October: has averaged +2.98%, up in 4 of 6 years. Past seasonality does not repeat on schedule.
Over the last 7 years, BNTX's strongest calendar month has been November (average +13.93%, up in 6 of 7 years) and its weakest January (average -3.46%, up in 3 of 7 years).
Average return for each calendar month over the last 7 years, from weekly closing prices with dividends included.
Long-term scenarios
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in BNTX, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in BNTX today could grow to about $29,254 by 2036 in the base case, with a 90th-percentile outcome near $221,940 and a 10th-percentile outcome around $3,856. Projections are statistical simulations, not guarantees.
BNTX Stock Price Prediction: 2030
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $134 for BNTX by 2030 in the base case, from $87.53 today (1.5x over 4 years). The 10th-percentile path ends near $37.33. These are outcomes of a Monte Carlo simulation run on BNTX's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $51.34 | $97.45 | $185 | |
| 2028 | $43.84 | $108 | $269 | |
| 2029 | $39.81 | $121 | $366 | |
| 2030 | $37.33 | $134 | $484 | |
| 2031 | $35.72 | $150 | $627 |
Method: a lognormal simulation of BNTX's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles. BNTX is highly volatile, so its upside column reaches an extreme multiple; treat it as a statistical tail, not an expectation.
Insider trading
What the people running the company have bought and sold.
BNTX insider trading
Shares the company's directors and officers bought and sold, from their own filings.
Month by month
Open-market purchases above the line, sales below.
Insider buying: No insider bought BNTX shares on the open market in the last 18 months. Sales are often planned in advance or cover tax on vesting shares, so they say less than purchases would.
As of October 16, 2026, BNTX insiders reported 12 open-market sales worth $74.3M and no open-market purchases over the last 18 months; grants and option exercises are not counted.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Oct 7, 2026 | Ugur Md Sahin
Chief Executive Officer
|
Sell | 24.0K | $2.3M |
| Oct 6, 2026 | Ugur Md Sahin
Chief Executive Officer
|
Sell | 93.0K | $9.0M |
| Sep 30, 2026 | Ugur Md Sahin
Chief Executive Officer
|
Sell | 66.0K | $6.5M |
| Sep 28, 2026 | Ugur Md Sahin
Chief Executive Officer
|
Sell | 61.0K | $6.0M |
| Sep 24, 2026 | Ugur Md Sahin
Chief Executive Officer
|
Sell | 69.0K | $6.8M |
| Sep 22, 2026 | Ugur Md Sahin
Chief Executive Officer
|
Sell | 79.0K | $7.9M |
| Sep 16, 2026 | Ugur Md Sahin
Chief Executive Officer
|
Sell | 49.0K | $4.7M |
| Sep 14, 2026 | Ugur Md Sahin
Chief Executive Officer
|
Sell | 86.0K | $8.4M |
| Sep 10, 2026 | Ugur Md Sahin
Chief Executive Officer
|
Sell | 20.5K | $2.0M |
| Sep 9, 2026 | Ugur Md Sahin
Chief Executive Officer
|
Sell | 73.0K | $7.2M |
| Sep 4, 2026 | Ugur Md Sahin
Chief Executive Officer
|
Sell | 76.5K | $7.9M |
| Apr 22, 2026 | Sierk Poetting
Chief Operating Officer
|
Sell | 50.0K | $5.5M |
Source: TwelveData, from reported insider filings
Questions people ask
Answered from the figures on this page, as of October 16, 2026.